Dr. Reddy’s (RDY) Laboratories announced that it has received a Notice of Compliance, NOC, from Health Canada for its generic Semaglutide Injection. Dr. Reddy’s becomes the first company to receive the market authorization for generic Semaglutide Injection in Canada, ahead of Health Canada’s review target date. The market authorization covers the 2 mg / pen and 4 mg / pen. With launch preparations underway, Dr. Reddy’s is well-positioned to bring this important treatment option available to Canadian patients.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RDY:
- Goldman downgrades Dr. Reddy’s to Sell on generic Ozempic concerns
- Dr. Reddy’s downgraded to Sell from Neutral at Goldman Sachs
- Dr. Reddy’s awaiting approval for Semaglutide in Canada, CNBC-TV18 says
- Dr. Reddy’s rally on CNBC report overstates upside, says Citi
- Dr. Reddy’s Board to Weigh Final FY 2025–26 Dividend on April 16 Disclosure